Lemaitre Vascular (LMAT) EBITDA (2010 - 2026)

Lemaitre Vascular (LMAT) has reported EBITDA for 17 consecutive years, with $20.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 26.37% year-over-year to $20.4 million in Q2 2026; TTM through Jun 2026 was $77.3 million, a 41.17% increase from a year earlier, with the FY2025 full-year figure at $67.9 million, up 29.96% from the prior year.
• EBITDA was $20.4 million for Q2 2026 at Lemaitre Vascular, up from $17.8 million in the prior quarter.
• Over five years, EBITDA peaked at $20.4 million in Q2 2026 and troughed at $5.8 million in Q2 2022.
• A 5-year average of $12.3 million and a median of $12.2 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 47.92% in 2022 and surged 63.42% in 2023, its largest moves.
• Over 5 years, EBITDA stood at $7.0 million in 2022, then surged by 46.49% to $10.2 million in 2023, then climbed by 25.95% to $12.9 million in 2024, then jumped by 46.51% to $18.8 million in 2025, then advanced by 8.32% to $20.4 million in 2026.
• The last three EBITDA figures came in at $20.4 million (Q2 2026), $17.8 million (Q1 2026), and $18.8 million (Q4 2025), per Business Quant data.